Introduction
Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at GIP and GLP-1 receptors. In the direct SURPASS-2 type 2 diabetes trial, tirzepatide produced -7.6 kg to -11.2 kg mean weight change at 40 weeks versus -5.7 kg with semaglutide 1 mg.
For obesity, STEP 1 and SURMOUNT-1 were separate studies, so their headline results are useful context but not a direct head-to-head answer.
What each option is approved to treat
Wegovy and Zepbound are the cited chronic weight-management products. Ozempic and Mounjaro are cited type 2 diabetes products. Semaglutide and tirzepatide differ in receptor activity, but the more useful first distinction is which exact FDA-approved product and indication match the clinical problem.
We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure
LIVE CATALOGCurrent telehealth prices and providers
Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $349, checked 20 October 2026 a month after 2 months at $199/month; plus $99/month care Visit provider Affiliate link · we may earn a commission | Wegovy® pen · Weekly injection · medication included Medication: $199/month for the first two months for eligible new self-pay patients at 0.25 or 0.5 mg, then $349/month. Offer ends December 31, 2026. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,349, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Wegovy® · Weekly branded injection · medication included The weight-loss category card prints $1,349 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,695, checked 22 October 2026 a month, continuing Visit provider | Wegovy® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($199–$349/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
- MEDGm: $99 membership + medication cost (medication total not published)Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $299, checked 20 October 2026 a month, continuing; plus $99/month care Visit provider Affiliate link · we may earn a commission | Zepbound® KwikPen · Weekly injection · medication included Medication dose prices: $299/month at 2.5 mg; $398 at 5 mg; $499 at 7.5 mg; $698 at 10, 12.5 or 15 mg. The calculation uses the 2.5 mg price; a dose change changes the total. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,069, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Zepbound® · Weekly branded injection · medication included The weight-loss category card prints $1,069 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,399, checked 22 October 2026 a month, continuing Visit provider | Zepbound® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($299–$449/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Gala Health | $1,299, checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly injection · medication included The Ozempic product page says From $1,299/month, cash price. It says insurance may reduce the cost. That page shows no other dollar price. Price source · checked 21 October 2026 |
| #2 RxSpan MD | $1,299, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly branded injection · medication included The weight-loss category card prints $1,299 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- MEDGm: $171 membership + medication cost (medication total not published)Medication or membership billed separately
- Shed Rx: Starting at $599/mo. Hero $149 is CMS template bleed.Last checked 14 Sept 2026Medication included as published
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- RxSpan MD: $1,069 / month; org catalog also marks this SKU sold outLast checked 14 Sept 2026Medication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What direct comparative evidence found
SURPASS-2 compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes. At 40 weeks, mean body-weight change was -7.6 kg, -9.3 kg, and -11.2 kg across tirzepatide groups, compared with -5.7 kg with semaglutide. That is direct diabetes evidence, not a direct obesity trial.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
The practical tradeoffs
Tirzepatide has the stronger weight-change result in SURPASS-2's diabetes population. Semaglutide has its own labeled products and evidence base. GI tolerance, diabetes regimen, eye history, pregnancy plans, oral medicines, route, access, and the approved indication can outweigh a single trial headline when choosing between them.
What separate obesity trials can answer
STEP 1 and SURMOUNT-1 support their own products in their own designs. They cannot create a direct obesity head-to-head claim.
| Question | Evidence-based check |
|---|---|
| Exact product | Confirm the approved product, formulation, and labeled indication |
| Evidence | Keep direct trials separate from indirect comparisons |
| Access | Verify provider terms and price basis independently |
Safety and interaction review
Contraindications, GI tolerance, eye history in diabetes, kidney-risk symptoms, oral medicines, pregnancy plans, and diabetes medicines can change the decision.
Use price after clinical clarity
Verified terms can help access planning, but must not imply that unlike formulations are clinically interchangeable.
What the cited sources establish
This comparison has one direct diabetes trial and separate obesity trials. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes; STEP 1 and SURMOUNT-1 each studied an obesity intervention in their own populations. Comparing their headlines as if they were one obesity head-to-head study would overstate the evidence.
The direct SURPASS-2 weight results favor tirzepatide in that type 2 diabetes study, but the decision still has several dimensions. Semaglutide may be discussed when its specific label and evidence fit the clinical goal; tirzepatide may be discussed when its specific label and evidence fit. The next useful comparison is the person's indication, diabetes regimen, GI tolerance, eye history, route preference, and ability to sustain follow-up.
The outcome comparison also depends on what is being measured. SURPASS-2 reports diabetes-trial weight change at 40 weeks, while STEP 1 and SURMOUNT-1 report separate obesity-trial outcomes at 68 and 72 weeks. A reader can use the direct trial to understand one diabetes comparison and the separate trials to understand each product's obesity evidence. Combining them into one leaderboard would hide the differences in dose, diagnosis, comparator, and study length.
Questions that change the next review
A pair-specific discussion should name the actual candidate products, then review indication, diabetes status, eye and GI history, other medicines, pregnancy plans, route, tolerability, and access. The key decision is not which molecule has the most dramatic average from an unrelated study design.
The direct-trial result is one input. The next decision turns on the diagnosis being treated, current diabetes medicines, eye and GI history, planned procedures, pregnancy plans, and route or access constraints.
Product details that still need verification
This page does not declare one medicine best for every reader or allow self-switching between products. It does not use a compounded formulation as a stand-in for an approved comparator. Any price or availability card is secondary to confirming the exact product and clinical fit.
SURPASS-2 is direct diabetes evidence, not a direct obesity trial. STEP 1 and SURMOUNT-1 should not be treated as a head-to-head contest. Safety, indication, history, access, and route matter. Compounded offers are not equivalent to approved products. Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist, but a treatment decision is not settled by mechanism or a headline result. The direct comparison cited here is in type 2 diabetes; obesity trials have different populations and designs. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about Semaglutide vs Tirzepatide: Evidence, Safety, Approved Uses, and Questions for Your Clinician?
- Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist, but a treatment decision is not settled by mechanism or a headline result. The direct comparison cited here is in type 2 diabetes; obesity trials have different populations and designs.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist, but a treatment decision is not settled by mechanism or a headline result. The direct comparison cited here is in type 2 diabetes; obesity trials have different populations and designs. The next step is a clinician-led review of the exact product and your situation.
Already on a wegovy plan? See which of 4 providers charge less than yours
Starting from scratch? How to get Zepbound injection online
Sources
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting semaglutide vs tirzepatide.
- Referenced primary clinical materialFDA · Accessed 28 August 2026
Source cited in the article section.
- Referenced primary clinical materialFDA · Accessed 28 August 2026
Source cited in the article section.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry